Download PDF
Intensivmedizin up2date 2018; 14(01): 39-51
DOI: 10.1055/s-0043-121035
Allgemeine Intensivmedizin
Georg Thieme Verlag KG Stuttgart · New York

Update: Immunsuppression bei Organtransplantationen

Daniela Kniepeiss
,
Alexander R. Rosenkranz
,
Peter Fickert
,
Peter Schemmer
Further Information

Publication History

Publication Date:
07 March 2018 (online)

Also available at
    Permissions and Reprints All articles of this category

Die Immunsuppression ist eine wesentliche Grundvoraussetzung für eine erfolgreiche Transplantation. Zur Reduktion der teils beträchtlichen Nebenwirkungen werden Kombinationstherapien mit unterschiedlichen Wirkstoffen durchgeführt. Dieser Beitrag soll einen aktuellen Überblick zur Immunsuppression nach Leber- und Nierentransplantation geben.
Kernaussagen

  • Etablierte Strategien zur Immunsuppression nach Organtransplantation haben in den letzten Jahren zu guten Ergebnissen geführt.

  • Eine Hauptrolle bei Immunsuppression nach Organtransplantation spielen Calcineurininhibitoren (CNI), die vor allem nephrotoxisch sind.

  • Es gibt mehrere Ansätze, die CNI-assoziierten Nebenwirkungen zu reduzieren und somit die Langzeitergebnisse weiter zu verbessern.

  • Konzepte für eine patientenorientierte Therapie müssen noch entwickelt werden.

Schlüsselwörter

Lebertransplantation - Nierentransplantation - Intensivmedizin - Immunsystem
 

  • Literatur

  • 1 Houben P, Gotthardt DN, Radeleff B. et al. [Complication management after liver transplantation: Increasing patient safety by standardized approach and interdisciplinary cooperation]. Chirurg 2015; 86: 139-145 doi:10.1007/s00104-014-2883-y
    Google Scholar
  • 2 Trunecka P, Klempnauer J, Bechstein WO. et al. Renal function in De Novo liver transplant recipients receiving different prolonged-release tacrolimus regimens – The DIAMOND study. Am J Transplant 2015; 15: 1843-1854
    CrossrefPubMedGoogle Scholar
  • 3 Tremblay S, Nigro V, Weinberg J. et al. A steady-state head-to-heaad pharmacokinetic comparison of all FK 506 (Tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period study. Am J Transplant 2017; 17: 432-442
    CrossrefPubMedGoogle Scholar
  • 4 Pietruck F, Abbud-Filho M, Vathsala A. et al. Conversion from MMF to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: results from three multicenter studies. Transplant Proc 2007; 39: 103-108
    CrossrefPubMedGoogle Scholar
  • 5 Winkler M, Ringe B, Schneider K. et al. Enhanced bioavailability of cyclosporine using a new oral formulation (Sandimmun optoral) in a liver-grafted patient with severe cholestasis. Transpl Int 1994; 7: 147-148
    CrossrefPubMedGoogle Scholar
  • 6 Starzl TE, Groth CG, Brettschneider L. et al. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168: 392-415
    CrossrefPubMedGoogle Scholar
  • 7 Richter S, Polychronidis G, Gotthardt DN. et al. Effect of delayed CNI-based immunosuppression with Advagraf ® on liver function after MELD-based liver transplantation (IMUTECT). BMC Surg 2014; 14: 64
    Google Scholar
  • 8 Döcke WD, Höflich C, Davis KA. et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005; 51: 2341-2347
    Google Scholar
  • 9 Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of UNOS registry data. Transplantation 2010; 90: 1511-1515
    Google Scholar
  • 10 Mangus RS, Fridell JA, Vianna RM. et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786-795
    CrossrefPubMedGoogle Scholar
  • 11 Zhang GQ, Zhang CS, Sun N. et al. Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials. Hepatobil Pancr Dis Int 2017; 16: 139-146
    Google Scholar
  • 12 Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int 2013; 26: 673-683
    Google Scholar
  • 13 Opelz G, Unterrainer C, Süsal C. et al. Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. Nephrol Dial Transplant 2016; 31: 1730-1738
    Google Scholar
  • 14 Adam R, Karam V, Delvart V. et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 2015; 15: 1267-1282
    CrossrefPubMedGoogle Scholar
  • 15 Kuypers DR, Peeters PC, Sennesael JJ. et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013; 95: 333-340
    CrossrefPubMedGoogle Scholar
  • 16 McAlister VC, Haddad E, Renouf E. et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578-1585
    Google Scholar
  • 17 Muduma G, Saunders R, Odeyemi I. et al. Systematic review and meta-analysis of Tacrolimus versus Ciclosporin as primary immunosuppression after liver transplant. PLoS One 2016; 11: e0160421
    CrossrefPubMedGoogle Scholar
  • 18 Rodriguez-Peralvarez M, Germani G, Darius T. et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2012; 12: 2797-2814
    Google Scholar
  • 19 Wang P, Que W, Li H. et al. Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction. Oncotarget 2017; 8: 57505-57515
    Google Scholar
  • 20 Wiesner R, Rabkin J, Klintmalm G. et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450
    CrossrefPubMedGoogle Scholar
  • 21 Karie-Guigues S, Janus N, Saliba F. et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083-1091
    Google Scholar
  • 22 Reich DJ, Clavien PA, Hodge EE. et al. MMF for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005; 80: 18-25
    CrossrefPubMedGoogle Scholar
  • 23 Beckebaum S, Cicinnati VR, Radtke A. et al. Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors?. Liver Int 2013; 33: 656-665
    CrossrefPubMedGoogle Scholar
  • 24 Saliba F, De Simone P, Nevens F. et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745
    CrossrefPubMedGoogle Scholar
  • 25 DeSimone P, Nevens F, De Carlis L. et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
    CrossrefPubMedGoogle Scholar
  • 26 Schnitzbauer A, Sothmann J, Baier L. et al. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07). Transplantation 2015; 99: 2565-2575
    CrossrefPubMedGoogle Scholar
  • 27 Sterneck M, Kaiser GM, Heyne N. et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant 2016; 30: 741-748
    Google Scholar
  • 28 Segev DL, Sozio SM, Shin EJ. et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525
    Google Scholar
  • 29 Liu YY, Li CP, Huai MS. et al. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression. PLoS One 2015; 10: e120939
    Google Scholar
  • 30 Klintmalm GB, Davis GL, Teperman L. et al. A randomized, multicentre study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403
    CrossrefPubMedGoogle Scholar
  • 31 Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance?. Curr Opin Organ Transplant 2017; 22: 97-104
    CrossrefPubMedGoogle Scholar
  • 32 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-S155
    PubMedGoogle Scholar
  • 33 Meier-Kriesche HU, Li S, Gruessner RWG. et al. Immunosuppression: evolution in practice and trends 1994–2004. Am J Transplant 2006; 6: 1111-1131
    Google Scholar
  • 34 Ekberg H, Tedesco-Silva H, Demirbas A. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
    Google Scholar
  • 35 De Fijter JW, Holdaas H, Oyen O. et al. Early conversion from calcineurin inhibitor – to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial. Am J Transplant 2017; 17: 1853-1867
    CrossrefPubMedGoogle Scholar
  • 36 Vincenti F, Charpentier B, Vanrenterghem Y. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546
    CrossrefPubMedGoogle Scholar
  • 37 Thomusch O, Wiesener M, Opgenoorth M. et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 2016; 17: 3006-3016
    Google Scholar
  • 38 Haller M, Royuela A, Nagler E. et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016; (08) CD005632
    PubMedGoogle Scholar
  • 39 Eskandary F, Bond G, Kozakowski N. et al. Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study. Transplantation 2017; 101: 631-641
    CrossrefPubMedGoogle Scholar
  • 40 Neuberger J, Bechstein W, Kuypers D. et al. Practical Recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report by the consensus on managing modifiable risk in transplantation (COMMIT) group. Transplantation 2017; 101 (4S Suppl 2): S1-S56
    PubMedGoogle Scholar
  • 41 Fine RN, Becker Y, DeGeest S. et al. Nonadherence Consensus Conference Summary Report. Am J Transplant 2009; 9: 35-41
    Google Scholar
  • 42 Lieber SR, Volk ML. Non-adherence and graft failure in adult liver transplant recipients. Dig Dis Sci 2013; 58: 824-834
    CrossrefPubMedGoogle Scholar
  • 43 Sellares J, de Freitas DG, Mengel M. et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399
    CrossrefPubMedGoogle Scholar
  • 44 Giese T, Zeier M, Schemmer P. et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 15: 339-344
    Google Scholar